James D. Anderson

Array ( [id] => 17503345 [patent_doc_number] => 20220096447 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => TREATMENT OF RESTENOSIS USING TEMSIROLIMUS [patent_app_type] => utility [patent_app_number] => 17/550538 [patent_app_country] => US [patent_app_date] => 2021-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11188 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17550538 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503377 [patent_doc_number] => 20220096479 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/549104 [patent_app_country] => US [patent_app_date] => 2021-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33072 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17549104 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503388 [patent_doc_number] => 20220096490 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM [patent_app_type] => utility [patent_app_number] => 17/547676 [patent_app_country] => US [patent_app_date] => 2021-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23728 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17547676 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18860118 [patent_doc_number] => 20230414552 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => NOVEL METHODS [patent_app_type] => utility [patent_app_number] => 18/266096 [patent_app_country] => US [patent_app_date] => 2021-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5784 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18266096 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19050747 [patent_doc_number] => 20240092716 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => CYCLOPENTENONES DERIVATIVES AND THEIR USE AS ANTIBIOTICS [patent_app_type] => utility [patent_app_number] => 18/265865 [patent_app_country] => US [patent_app_date] => 2021-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11230 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18265865 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17475039 [patent_doc_number] => 20220082543 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-17 [patent_title] => ANALYSIS METHOD OF 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE ACTIVE PHARMACEUTICAL INGREDIENT, TREATMENT FOR AMYOTROPHIC LATERAL SCLEROSIS, INHIBITION OF PROGRESSION OF AMYOTROPHIC LATERAL SCLEROSIS, AND METHOD OF PRODUCING MEDICAMENT CONTAINING 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE ACTIVE PHARMACEUTICAL INGREDIENT [patent_app_type] => utility [patent_app_number] => 17/536947 [patent_app_country] => US [patent_app_date] => 2021-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12500 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 329 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17536947 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18815895 [patent_doc_number] => 20230390234 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => COMPOSITION INHIBITING MUSCLE LOSS OR PROMOTING MUSCLE FORMATION THROUGH SKIN-DERIVED EXOSOMES [patent_app_type] => utility [patent_app_number] => 17/909877 [patent_app_country] => US [patent_app_date] => 2021-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5700 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17909877 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17576811 [patent_doc_number] => 20220133666 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => METHODS OF TREATMENT OF CHOLESTATIC DISEASES [patent_app_type] => utility [patent_app_number] => 17/533767 [patent_app_country] => US [patent_app_date] => 2021-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10516 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17533767 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17458625 [patent_doc_number] => 20220071929 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => APPLICATION OF R-KETAMINE AND SALT THEREOF AS PHARMACEUTICALS [patent_app_type] => utility [patent_app_number] => 17/527693 [patent_app_country] => US [patent_app_date] => 2021-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10877 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17527693 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17441781 [patent_doc_number] => 20220062286 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => USE OF RNAI INHIBITING PARP ACTIVITY FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/528034 [patent_app_country] => US [patent_app_date] => 2021-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7036 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17528034 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17670862 [patent_doc_number] => 20220184029 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING NEUROBLASTOMA [patent_app_type] => utility [patent_app_number] => 17/519398 [patent_app_country] => US [patent_app_date] => 2021-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13168 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17519398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18806845 [patent_doc_number] => 20230381178 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => METHODS FOR IMPROVING RENAL FUNCTION WITH A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM DEPENDENT GLUCOSE TRANSPORT 2 INHIBITOR [patent_app_type] => utility [patent_app_number] => 18/032450 [patent_app_country] => US [patent_app_date] => 2021-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9804 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18032450 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503374 [patent_doc_number] => 20220096476 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => Pharmaceutical Composition For The Treatment Of Pulmonary Arterial Hypertension [patent_app_type] => utility [patent_app_number] => 17/515132 [patent_app_country] => US [patent_app_date] => 2021-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13741 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17515132 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18806845 [patent_doc_number] => 20230381178 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => METHODS FOR IMPROVING RENAL FUNCTION WITH A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM DEPENDENT GLUCOSE TRANSPORT 2 INHIBITOR [patent_app_type] => utility [patent_app_number] => 18/032450 [patent_app_country] => US [patent_app_date] => 2021-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9804 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18032450 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17412703 [patent_doc_number] => 20220047607 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => METHODS OF TREATING NEURODEVELOPMENTAL DISORDERS [patent_app_type] => utility [patent_app_number] => 17/511058 [patent_app_country] => US [patent_app_date] => 2021-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8956 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17511058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17398101 [patent_doc_number] => 20220040191 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => METHODS, COMPOSITIONS AND DEVICES FOR TREATING CANCER WITH ILLUDOFULVENES [patent_app_type] => utility [patent_app_number] => 17/508729 [patent_app_country] => US [patent_app_date] => 2021-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43852 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 183 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17508729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17398205 [patent_doc_number] => 20220040295 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => Treatment of Cancer With Naltrexone [patent_app_type] => utility [patent_app_number] => 17/508590 [patent_app_country] => US [patent_app_date] => 2021-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4890 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17508590 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17441799 [patent_doc_number] => 20220062304 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => Methods of vitamin D treatment [patent_app_type] => utility [patent_app_number] => 17/498496 [patent_app_country] => US [patent_app_date] => 2021-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15324 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17498496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19026302 [patent_doc_number] => 11925642 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-12 [patent_title] => Regulation of eIF4E activity for migraine therapy [patent_app_type] => utility [patent_app_number] => 17/495902 [patent_app_country] => US [patent_app_date] => 2021-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 11445 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17495902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18368093 [patent_doc_number] => 11648240 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-16 [patent_title] => Pharmaceutical composition comprising famotidine, lidocaine and melatonin [patent_app_type] => utility [patent_app_number] => 17/488238 [patent_app_country] => US [patent_app_date] => 2021-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11690 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17488238 [rel_patent_id] =>[rel_patent_doc_number] =>)